Comparison of the FDA and EMA guidance on drug development in ulcerative colitis: an expert panel review.

Vieujean S, Sands BE, Panaccione R, Rubin DT, Jairath V, Danese S, Peyrin-Biroulet L, Schreiber S, Vermeire S, D'Haens G, Dignass A, Dulai PS, Narula N, Reinisch W

Open source

DOI: 10.1093/ecco-jcc/jjaf111
Published: 2025 Jul 3
Container: Journal of Crohn's & colitis
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1093/ecco-jcc/jjaf111,
  title = {Comparison of the FDA and EMA guidance on drug development in ulcerative colitis: an expert panel review.},
  author = {Vieujean S and Sands BE and Panaccione R and Rubin DT and Jairath V and Danese S and Peyrin-Biroulet L and Schreiber S and Vermeire S and D'Haens G and Dignass A and Dulai PS and Narula N and Reinisch W},
  year = {2025},
  journal = {Journal of Crohn's \& colitis},
  doi = {10.1093/ecco-jcc/jjaf111},
  url = {https://doi.org/10.1093/ecco-jcc/jjaf111}
}

RIS

TY  - JOUR
TI  - Comparison of the FDA and EMA guidance on drug development in ulcerative colitis: an expert panel review.
AU  - Vieujean S
AU  - Sands BE
AU  - Panaccione R
AU  - Rubin DT
AU  - Jairath V
AU  - Danese S
AU  - Peyrin-Biroulet L
AU  - Schreiber S
AU  - Vermeire S
AU  - D'Haens G
AU  - Dignass A
AU  - Dulai PS
AU  - Narula N
AU  - Reinisch W
PY  - 2025
JO  - Journal of Crohn's & colitis
DO  - 10.1093/ecco-jcc/jjaf111
UR  - https://doi.org/10.1093/ecco-jcc/jjaf111
ER  -

APA

S, V., BE, S., R, P., DT, R., V, J., S, D., L, P., S, S., S, V., G, D., A, D., PS, D., N, N., & W, R. (2025). Comparison of the FDA and EMA guidance on drug development in ulcerative colitis: an expert panel review.. Journal of Crohn's & colitis. https://doi.org/10.1093/ecco-jcc/jjaf111

Source records

pubmed · retrieved 2026-09-26T11:15:11.854Z